Form 4: SOPHiA GENETICS CMO Sells Shares for Tax Obligations

SOPHiA GENETICS' Chief Medical Officer, Philippe Menu, sold 608 ordinary shares on March 19, 2026, at a weighted average price of $4.7908 to cover tax liabilities from restricted stock unit vesting.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported a sale of 608 ordinary shares.
• The transaction occurred on March 19, 2026, at a weighted average price of $4.7908 per share.
• The shares were sold to satisfy tax obligations related to the vesting of restricted stock units on March 18, 2026.
• This sale was executed under a pre-established Rule 10b5-1 trading plan, indicating it was not a discretionary trade.
• Following the transaction, Philippe Menu beneficially owns 173,616 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction to cover tax liabilities from RSU vesting, not indicative of management's sentiment towards the company's future.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan, particularly those for tax obligations related to RSU vesting, are common occurrences across industries. Such transactions are generally considered non-discretionary and typically do not signal a change in management's confidence in the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Minimal impact on shareholders as the sale is small (608 shares) and non-discretionary, primarily for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this routine insider transaction.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale of a small number of shares by an insider to cover tax obligations related to RSU vesting. It does not provide new information that would warrant a change in investment thesis or a strong buy/sell recommendation. Investors should continue to hold based on the company's fundamental performance rather than this specific insider transaction.

Keywords

SOPHiA GENETICS, SOPH, Form 4, Insider Trading, Share Sale, Restricted Stock Units, Tax Obligations, Philippe Menu, Rule 10b5-1 Plan